Cited by 180Organ Transplantation Techniques and OutcomesTransplantation: Methods and OutcomesLiver Disease and Transplantation

Factors associated with major adverse cardiovascular events after liver transplantation among a national sample

Open access
VanWagner, L.B., Serper, M., Kang, R., Levitsky, J., Hohmann, S., Abecassis, M., Skaro, A., Lloyd-Jones, D.M.·2016·American Journal of Transplantation

Abstract

Assessment of major adverse cardiovascular events (MACE) after liver transplantation (LT) has been limited by the lack of a multicenter study with detailed clinical information. An integrated database linking information from the University HealthSystem Consortium and the Organ Procurement and Transplant Network was analyzed using multivariate Poisson regression to assess factors associated with 30- and 90-day MACE after LT (February 2002 to December 2012). MACE was defined as myocardial infarction (MI), heart failure (HF), atrial fibrillation (AF), cardiac arrest, pulmonary embolism, and/or stroke. Of 32 810 recipients, MACE hospitalizations occurred in 8% and 11% of patients at 30 and 90 days, respectively. Recipients with MACE were older and more likely to have a history of nonalcoholic steatohepatitis (NASH), alcoholic cirrhosis, MI, HF, stroke, AF and pulmonary and chronic renal disease than those without MACE. In multivariable analysis, age >65 years (incidence rate ratio [IRR] 2.8, 95% confidence interval [95% CI] 1.8-4.4), alcoholic cirrhosis (IRR 1.6, 95% CI 1.2-2.2), NASH (IRR 1.6, 95% CI 1.1-2.4), pre-LT creatinine (IRR 1.1, 95% CI 1.04-1.2), baseline AF (IRR 6.9, 95% CI 5.0-9.6) and stroke (IRR 6.3, 95% CI 1.6-25.4) were independently associated with MACE. MACE was associated with lower 1-year survival after LT (79% vs. 88%, p < 0.0001). In a national database, MACE occurred in 11% of LT recipients and had a negative impact on survival. Pre-LT AF and stroke substantially increase the risk of MACE, highlighting potentially high-risk LT candidates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ajt.13779

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liver transplant recipients with T2D and chronic kidney disease are at the highest risk for cardiovascular events.

    “Cardiovascular complications are the second most common cause of non-hepatic mortality in liver transplant recipients, 512 and those with T2D 513 and chronic kidney disease 514 are at the highest risk for cardiovascular events.”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [513]

    The Results section (page unavailable) reports that recipients with early cardiovascular events had a higher prevalence of chronic renal disease than those without events (19% versus 14%), and that pre-transplant creatinine independently predicted early events. It does not identify recipients with chronic kidney disease as being at the highest risk; atrial fibrillation and prior stroke had much larger reported risk estimates. The T2D portion is attached to a different citation. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
VanWagner, L. B., Serper, M., Kang, R., Levitsky, J., Hohmann, S., Abecassis, M., Skaro, A., & Lloyd-Jones, D. M.
Affiliations
  • Northwestern University (US)
  • Hospital of the University of Pennsylvania (US)
  • University HealthSystem Consortium (US)
Corresponding author
VanWagner, L.B.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2016-09
Volume
16
Issue
9
Pages
2684-2694
ISSN
1600-6135 (ISSN-L)
OpenAlex
W2294860106
Cited by
180
References
49
Citations by year
2026: 15 · 2025: 14 · 2024: 21 · 2023: 14 · 2022: 22 · 2021: 21 · 2020: 20 · 2019: 16 · 2018: 19 · 2017: 14 · 2016: 3 · 2014: 1
FWCI
19.19
Type
journal article
Language
en
Open access
Locations
  • American Journal of Transplantation (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1 F32 HL116151‐01)
  • American Liver Foundation
  • National Center for Advancing Translational Sciences (KL2TR001424)
Topics
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
liver transplantation, major adverse cardiovascular events, atrial fibrillation, stroke, alcoholic cirrhosis, nonalcoholic steatohepatitis, post-transplant survival, risk factors
MeSH terms
Adolescent, Adult, Aged, Atrial Fibrillation, Female, Follow-Up Studies, Graft Survival, Heart Failure, Humans, Liver Diseases, Male, Middle Aged, Myocardial Infarction, Prognosis, Retrospective Studies, Risk Factors, Liver Transplantation, Risk Assessment, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review